耳畸蛋白基因治疗听力损失
本文综述了耳畸蛋白(OTOF)基因突变所致遗传性耳聋的基因治疗进展,涵盖OTOF蛋白功能、致病机制、自然病史及临床前与临床试验结果。动物模型显示靶向内毛细胞可行且耳蜗结构完整,近期OTOF基因治疗的成功为遗传性耳聋治疗提供了概念验证。
要点
- OTOF突变导致严重耳聋但外毛细胞长期存活,适合基因治疗。
- 靶向内毛细胞的基因递送在动物模型中可行且耳蜗结构完整。
- 近期OTOF基因治疗临床试验初步显示可安全有效改善听力。
核心结论
- OTOF基因治疗在动物模型和早期临床试验中显示出改善听力的潜力和安全性,为遗传性耳聋治疗提供概念验证。
研究设计与样本
- 综述性文章,汇总OTOF蛋白功能、OTOF致病变异、自然病史、临床前研究及当前人体临床试验结果。
主要发现
- OTOF突变导致严重耳聋时,听觉外毛细胞常于出生后多年内保留。
- 基因递送靶细胞内毛细胞在动物模型中存在且存活,所在器官结构完整且功能存在。
- 近期OTOF基因治疗报告了显著成功,证明可有效且安全地改善听力。
临床怎么用
- 为耳鼻咽喉科医生评估OTOF相关耳聋患者是否适合基因治疗提供背景知识。
- 提示对OTOF突变致聋患者需关注内毛细胞和外毛细胞状态评估。
局限性
- 本文为综述,未报告原始研究的具体样本量、效应量或统计阈值。
- 人体临床试验结果仅为当前阶段报告,长期疗效和安全性未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the last decade, gene therapy has shown promise in treating many genetic disorders. Hereditary hearing impairment represents one of the next promising frontiers. Many initial development efforts have focused on hearing impairment caused by mutations in the otoferlin gene ( OTOF ), as these mutations cause profound deafness in the setting of preserved auditory outer hair cells, which often remain for many years after birth. Animal models have shown that the target cells for gene delivery, the inner hair cells, are also present and viable, and they reside in a structurally intact organ that is otherwise functional. Recent remarkable successes reported with OTOF gene therapy serve as proof of concept that gene therapy can effectively and safely improve hearing for this and likely other forms of genetic deafness. Here, the authors review the otoferlin protein and its role in hearing, the role of pathogenic variants in OTOF in hearing loss, the natural history of the condition, and the results of preclinical studies and of current human clinical trials of OTOF gene therapy.
引用
- Devare J, Lawrence AP, Germiller JA, et al. Otoferlin Gene Therapy for Hearing Loss. Ear Hear. 2026. PMID: 42868222. doi:10.1097/AUD.0000000000001861
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。